saruparib saruparib PHASE3
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaOncology
Peak Sales Est$1000M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: PARP1 selective inhibitor
Expert: PARP1-selective inhibitor designed to minimize PARP2-mediated hematological toxicity while maintaining synthetic lethality in HRD tumors.
Everyday: A more targeted version of PARP inhibitors that may have fewer side effects.
Targets: ["PARP1"]
Programs (2)
IndicationStageKey StudyRegional Status
OC (Pt-sens)PHASE3PETRA[]
mCRPCPHASE2PARP-CRPC[]
Notes
PARP inhibitor.
Data from Supabase · Updated 2026-03-24